189 related articles for article (PubMed ID: 28665508)
1. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
[TBL] [Abstract][Full Text] [Related]
2. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Crespo I; Gich I; Rodríguez J; Webb SM
Clin Endocrinol (Oxf); 2012 Nov; 77(5):735-42. PubMed ID: 22533782
[TBL] [Abstract][Full Text] [Related]
3. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
4. Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome.
Vega-Beyhart A; Laguna-Moreno J; Díaz-Catalán D; Boswell L; Mora M; Halperin I; Casals G; Hanzu FA
Front Endocrinol (Lausanne); 2022; 13():833644. PubMed ID: 35282465
[TBL] [Abstract][Full Text] [Related]
5. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
Engelhardt D; Weber MM
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
[TBL] [Abstract][Full Text] [Related]
6. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
[TBL] [Abstract][Full Text] [Related]
8. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
9. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing's syndrome.
Daniel E; Newell-Price JD
Eur J Endocrinol; 2015 Jun; 172(6):R263-80. PubMed ID: 25637072
[TBL] [Abstract][Full Text] [Related]
10. Metyrapone treatment in Cushing's syndrome: a real-life study.
Ceccato F; Zilio M; Barbot M; Albiger N; Antonelli G; Plebani M; Watutantrige-Fernando S; Sabbadin C; Boscaro M; Scaroni C
Endocrine; 2018 Dec; 62(3):701-711. PubMed ID: 30014438
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review.
Iwayama H; Hirase S; Nomura Y; Ito T; Morita H; Otake K; Okumura A; Takagi J
BMC Endocr Disord; 2018 Mar; 18(1):19. PubMed ID: 29587720
[TBL] [Abstract][Full Text] [Related]
12. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M; Castinetti F
Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
[TBL] [Abstract][Full Text] [Related]
13. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
14. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
15. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome.
Moncet D; Morando DJ; Pitoia F; Katz SB; Rossi MA; Bruno OD
Medicina (B Aires); 2007; 67(1):26-31. PubMed ID: 17408017
[TBL] [Abstract][Full Text] [Related]
16. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
17. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole.
Corcuff JB; Young J; Masquefa-Giraud P; Chanson P; Baudin E; Tabarin A
Eur J Endocrinol; 2015 Apr; 172(4):473-81. PubMed ID: 25624013
[TBL] [Abstract][Full Text] [Related]
18. Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN.
Valassi E; Franz H; Brue T; Feelders RA; Netea-Maier R; Tsagarakis S; Webb SM; Yaneva M; Reincke M; Droste M; Komerdus I; Maiter D; Kastelan D; Chanson P; Pfeifer M; Strasburger CJ; Tóth M; Chabre O; Krsek M; Fajardo C; Bolanowski M; Santos A; Trainer PJ; Wass JAH; Tabarin A;
Eur J Endocrinol; 2018 Apr; 178(4):399-409. PubMed ID: 29440375
[TBL] [Abstract][Full Text] [Related]
19. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
20. [Cushing's syndrome: clinical study of fifteen cases].
Calvo Romero JM; Morales Pérez F; Alvarez Barreiro JA; Diaz Pérez de Madrid J
An Med Interna; 1998 May; 15(5):237-40. PubMed ID: 9629768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
